Skip to main content
Erschienen in: Immunologic Research 5/2021

06.08.2021 | COVID-19 | Commentary Zur Zeit gratis

COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators

verfasst von: Mina T. Kelleni

Erschienen in: Immunologic Research | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

In this manuscript, COVID-19, Ebola virus disease, Nipah virus infection, SARS, and MERS are suggested to be considered for a novel immunological reclassification as acute onset immune dysrhythmia syndrome (n-AIDS) due to altered monocytic, Th1/Th2, as well as cytokines and chemokines balances. n-AIDs is postulated to be the cause of the acute respiratory distress and multi-inflammatory syndromes which are described with fatal COVID-19, and immunomodulators are suggested to effectively manage the mentioned diseases as well as for other disorders caused by Th1/Th2 imbalance. Meanwhile, para COVID syndrome is suggested to describe various immune-related complications, whether before or after recovery, and to embrace a potential of a latent infection, that might be discovered later, as occurred with Ebola virus disease. Finally, our hypothesis has evolved out of our real-life practice that uses immunomodulatory drugs to manage COVID-19 safely and effectively.
Literatur
1.
Zurück zum Zitat Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14(3):107–11.CrossRef Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14(3):107–11.CrossRef
3.
Zurück zum Zitat Rupp J, et al. T cell phenotyping in individuals hospitalized with COVID-19. J Immunol. 2021;206:1478.CrossRef Rupp J, et al. T cell phenotyping in individuals hospitalized with COVID-19. J Immunol. 2021;206:1478.CrossRef
4.
Zurück zum Zitat Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.CrossRef Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.CrossRef
5.
Zurück zum Zitat Sami R, et al. Characterizing the immune responses of those who survived or succumbed to COVID-19: can immunological signatures predict outcome? Cytokine. 2021;140:155439.CrossRef Sami R, et al. Characterizing the immune responses of those who survived or succumbed to COVID-19: can immunological signatures predict outcome? Cytokine. 2021;140:155439.CrossRef
6.
Zurück zum Zitat Gupta A. Is immuno-modulation the key to COVID-19 pandemic? Indian J Orthopaedics. 2020;54(3):394–7.CrossRef Gupta A. Is immuno-modulation the key to COVID-19 pandemic? Indian J Orthopaedics. 2020;54(3):394–7.CrossRef
7.
Zurück zum Zitat Neidleman J, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. MedRxiv. 2021;587:270. Neidleman J, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. MedRxiv. 2021;587:270.
8.
Zurück zum Zitat Gadotti AC, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171–198171.CrossRef Gadotti AC, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171–198171.CrossRef
9.
Zurück zum Zitat Galani I-E, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2021;22(1):32–40.CrossRef Galani I-E, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol. 2021;22(1):32–40.CrossRef
10.
Zurück zum Zitat Lopez L, et al. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433.CrossRef Lopez L, et al. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433.CrossRef
12.
Zurück zum Zitat Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.CrossRef
13.
Zurück zum Zitat Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.CrossRef Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.CrossRef
15.
Zurück zum Zitat Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591:92–8.CrossRef Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591:92–8.CrossRef
17.
Zurück zum Zitat Lou B, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763.CrossRef Lou B, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763.CrossRef
19.
Zurück zum Zitat Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.CrossRef Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.CrossRef
20.
Zurück zum Zitat Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.e1039.CrossRef Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.e1039.CrossRef
22.
Zurück zum Zitat Pietsch H, et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis. 2021;102:70–2.CrossRef Pietsch H, et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis. 2021;102:70–2.CrossRef
23.
Zurück zum Zitat Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636–44.CrossRef Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636–44.CrossRef
24.
Zurück zum Zitat Taquet M, et al. 6-month neurological and psychiatric outcomes in survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.CrossRef Taquet M, et al. 6-month neurological and psychiatric outcomes in survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.CrossRef
25.
Zurück zum Zitat Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51:296.CrossRef Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51:296.CrossRef
26.
Zurück zum Zitat Tavazzi G, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911–5.CrossRef Tavazzi G, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911–5.CrossRef
27.
Zurück zum Zitat Liegeois M, et al. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91–6.CrossRef Liegeois M, et al. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91–6.CrossRef
28.
Zurück zum Zitat Falasca L, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–9.CrossRef Falasca L, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–9.CrossRef
29.
Zurück zum Zitat Wiedemann A, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.CrossRef Wiedemann A, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.CrossRef
30.
Zurück zum Zitat Colavita F, et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014–2016 outbreak in West Africa. Viruses. 2019;11(4):373.CrossRef Colavita F, et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014–2016 outbreak in West Africa. Viruses. 2019;11(4):373.CrossRef
32.
Zurück zum Zitat Satterfield BA, et al. The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun. 2015;6(1):7483.CrossRef Satterfield BA, et al. The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun. 2015;6(1):7483.CrossRef
33.
Zurück zum Zitat Prescott J, et al. The immune response to Nipah virus infection. Adv Virol. 2012;157(9):1635–41. Prescott J, et al. The immune response to Nipah virus infection. Adv Virol. 2012;157(9):1635–41.
34.
Zurück zum Zitat Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.CrossRef Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.CrossRef
35.
Zurück zum Zitat Saleemi MA, et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104583–104583. Saleemi MA, et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104583–104583.
36.
Zurück zum Zitat Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. 2020;67(4):1414–5.CrossRef Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. 2020;67(4):1414–5.CrossRef
38.
Zurück zum Zitat Bixler SL, et al. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9(3):299–317.CrossRef Bixler SL, et al. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9(3):299–317.CrossRef
Metadaten
Titel
COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators
verfasst von
Mina T. Kelleni
Publikationsdatum
06.08.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Immunologic Research / Ausgabe 5/2021
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-021-09219-y

Weitere Artikel der Ausgabe 5/2021

Immunologic Research 5/2021 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.